This implies that passive immunization with tau antibodies can be a practical therapeutic target and which the CSF volume of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to watch tau therapeutics in scientific trials. Or you are able to p